Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 3/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 6/20 | 0.34 |
| ▸ | NOS3 | P29474 | 4/20 | 0.34 |
| ▸ | NOS1 | P29475 | 4/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | GCLC | P48506 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15384688 | 0.82 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1NOS2NOS3 | |
| SCHEMBL24213302 | 0.78 | NOS2 (0.33) | SLC1A3SLC1A2SLC1A1NOS2NOS3 | |
| SCHEMBL22387071 | 0.78 | NOS2 (0.33) | SLC1A3SLC1A2SLC1A1NOS2NOS3 | |
| SCHEMBL20099156 | 0.77 | BHMT (0.41) | SLC1A3SLC1A2SLC1A1NOS2NOS3 | |
| SCHEMBL24125927 | 0.76 | ALDH1A1 (0.37) | SLC1A3SLC1A2SLC1A1NOS2NOS3 | |
| SCHEMBL6367974 | 0.75 | — | — | |
| SCHEMBL14886193 | 0.75 | — | — | |
| SCHEMBL8299449 | 0.75 | — | — | |
| SCHEMBL2632763 | 0.75 | — | — | |
| SCHEMBL5928059 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897721-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7473760-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | VIP, GNRHR, NPR1 | SLC1A3 1046/4885SLC1A2 1932/4885SLC1A1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.